| Basics |
Merus N.V.
Merus NV is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics.
|
| IPO Date: |
May 19, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$7.22B |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$0.62 | 2.71%
|
| Avg Daily Range (30 D): |
$0.20 | 0.21%
|
| Avg Daily Range (90 D): |
$0.75 | 1.15%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.28M |
| Avg Daily Volume (30 D): |
3.63M |
| Avg Daily Volume (90 D): |
1.6M |
| Trade Size |
| Avg Trade Size (Sh.): |
88 |
| Avg Trade Size (Sh.) (30 D): |
145 |
| Avg Trade Size (Sh.) (90 D): |
106 |
| Institutional Trades |
| Total Inst.Trades: |
2,990 |
| Avg Inst. Trade: |
$2.38M |
| Avg Inst. Trade (30 D): |
$4.22M |
| Avg Inst. Trade (90 D): |
$3.78M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.53M |
| Avg Closing Trade (30 D): |
$7.33M |
| Avg Closing Trade (90 D): |
$4.96M |
| Avg Closing Volume: |
50.34K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-1.26
|
$-2.23
|
|
Diluted EPS
|
|
$-1.26
|
$-2.23
|
|
Revenue
|
$
|
$ 12.15M
|
$ 8.83M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -95.52M
|
$ -158.22M
|
|
Operating Income / Loss
|
$
|
$ -96.48M
|
$ -110.35M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -75.3M
|
$ 245.63M
|
|
PE Ratio
|
|
|
|
|
|
|
